CLX Medical, Inc. (CLXN) Announces Status of Validation Study for Zonda, Inc.'s Rapid Point of Care Test for Chlamydia
6/17/2008 11:48:21 AM
MURRIETA, CA--(MARKET WIRE)--Jun 17, 2008 -- CLX Medical, Inc. (OTC BB:CLXN.OB - News), which is focused on the launch and distribution of unique medical diagnostic testing products, today provided an update on the pre-clinical trials validation study for Zonda Incorporated's rapid point of care test for chlamydia. A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.
comments powered by